ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
A phase 2 trial of HS-20093 in head and neck squamous cell carcinoma, run by Hansoh BioMedical R&D Company, now recruiting.
Overview
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06007729 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-12. Interventions recorded: HS-20093. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
ARTEMIS-006: A Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Administration of HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase
Phase 2
Sponsor
Hansoh BioMedical R&D Company
Registry
Enrolled
170